v3.26.3
ACQUIRED IN PROCESS RESEARCH AND DEVELOPMENT
9 Months Ended
Sep. 30, 2026
Acquired In Process Research And Development  
ACQUIRED IN PROCESS RESEARCH AND DEVELOPMENT

6. ACQUIRED IN PROCESS RESEARCH AND DEVELOPMENT

 

During March 2025, the Company entered into an agreement with Gensignia Life Sciences Inc. to buy the entire issued share capital of Gensignia IP Limited (the “GIP Shares”) from Gensignia Life Sciences Inc., together with all records and intellectual property relating to Gensignia’s interest in proprietary microRNA Signature Classifier (“MSC”) test. The Company agreed and issued 3,750,000 shares at $0.40 as consideration for the same.

 

During the quarter ending September 30, 2026, this transaction was completed. The Company has determined that this transaction should be treated as an expense, with the acquired In-Process Research and Development (“IPR&D”) assets, determined not to have an alternate future use to the MSC that the Company is developing and as such is required to be expensed under ASC 730.